Stocks Health care IMUX

NASDAQ · Health care

Immunic, Inc. (IMUX)

It posted a net loss of $111.6M. In fiscal 2025 capital spending exceeded operating cash flow by $86M. At June 30, 2026 it held $155.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

Watch IMUX in 60 seconds

Follow IMUX

Free, no password. An email when IMUX files with the SEC.

Key facts about Immunic, Inc.

Net worth

Immunic, Inc. has a market value (market cap) of $109.7M at the latest share price, and shareholders' equity of $127.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Cash flow

In fiscal 2025 operations used $85.8M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

Next earnings report

Immunic, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

What Immunic, Inc. does

Immunic, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IMUX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Immunic, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. November 5, 2026
   Investor disclosure 8-K
2. November 2, 2026
   Passive stake changed SCHEDULE 13G/A
3. October 1, 2026
   Employee stock plan registration S-8
4. September 11, 2026
   Executive or director change 8-K
5. September 9, 2026
   Investor disclosure 8-K
6. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
7. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
8. August 14, 2026
   Passive stake changed SCHEDULE 13G/A
9. August 13, 2026
   Passive stake changed SCHEDULE 13G/A
10. August 12, 2026
    Employee stock plan registration S-8

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 18, 2026. Insider transactions on SEC

Insider trades

What the people running Immunic, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns IMUX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Soleus Capital Master Fund, L.P. 4.9% (August 13, 2026); Alyeska Investment Group, L.P. 4.85% (May 15, 2026); 683 Capital Management, LLC 3.4% (May 15, 2026); Soleus Capital Management, L.P. 1.6% (November 7, 2025); RTW Investments, LP 1.1% (May 15, 2025).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 55 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about IMUX

What does Immunic, Inc. do?

Immunic, Inc. is a company in the Health care sector, listed on NASDAQ as IMUX. Its shares trade on NASDAQ under the ticker IMUX.

What is Immunic, Inc.'s net worth?

Immunic, Inc. has a market value (market cap) of $109.7M at the latest share price, and shareholders' equity of $127.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Immunic, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $111.6M.

When did Immunic, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from November 5, 2026.

When is Immunic, Inc.'s next earnings report?

Immunic, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare IMUX with

Compare IMUX with any company

Follow IMUX

Get an email when Immunic, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow IMUX

Free, no password. An email when IMUX files with the SEC.

Where the numbers come from

Financial figures are the values Immunic, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.